@article{f78cd52758be4120be7a9b100687c42a,
title = "Targeting Approaches of Nanomedicines in Acute Myeloid Leukemia",
abstract = "Acute myeloid leukemia (AML) is a hematological malignancy, which is commonly associated with high incidence and mortality among adult patients. The standard induction regimen for AML has been substantially unchanged over the past 40 years, for which novel nanomedicines have represented a promising strategy in AML therapies. Despite developments of multiple nanoparticles formulated with drugs or genes, less there is not much information available about approaches in AML is available. This review presents an overview of nanomedicines currently being evaluated in AML. First, it briefly summarized conventional chemotherapies in use. Second, nanomedicines presently ongoing in clinical trials or preclinical researches were classified and described, with illustrative examples from recent literatures. Finally, limitations and potential safety issues concerns in clinical translation of AML treatment were discussed as well.",
keywords = "acute myeloid leukemia, cancer therapy, nanomedicines, nanoparticles",
author = "Xiao Huang and Hai Lin and Feng Huang and Yuning Xie and Wong, {Ka Hong} and Xiaoyu Chen and Dongyue Wu and Aiping Lu and Zhijun Yang",
note = "Funding Information: Acute myeloid leukemia has been considered an intricate hematological malignancy with poor responses and high mortalities. Chemotherapies, targeting therapies, and immunotherapies are the conventional treatment strategies for AML. This review summarized current development and approaches of nanomedicines in AML, including related technologic rationale, efficacies, safety profiles, and limitations, which may provide a novel and highlighted therapeutic option for AML treatment in future. Previous studies have demonstrated a superior for that NPs can be superior in improving bioavailability, reducing adverse effects, and circumventing drug resistances. Liposomal and polymeric NPs have shown especially promising prospects with advantages of strengthened loading ability and drug-release controlling. Chemical formulations and specific ligands such as antibodies or CPPs are also in underdevelopment. On the contrary, due to physical properties, drugs decorated with metal or silica NPs are less biocompatible and biodegradable, which restrict their utilization in AML. However, according to encouraging results in clinical trials, we could inference that NPs may finally become a promising and clinically acceptable option in the treatment of AML. Author{\textquoteright}s Note Feng Huang is also affiliated with Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, Beijing, China. Declaration of Conflicting Interests The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. Funding The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study is supported by grants from Hong Kong Baptist University Special Development Fund (SDF18-0319-P03). ORCID iD Xiao Huang https://orcid.org/0000-0002-6144-2860 ",
year = "2019",
month = oct,
day = "1",
doi = "10.1177/1559325819887048",
language = "English",
volume = "17",
pages = "1--14",
journal = "Dose-Response",
issn = "1559-3258",
publisher = "International Dose-Response Society",
number = "4",
}
